GlaxoSmithKline , a specialist developer of vaccine platform technologies for $325 million, the company stated in a press release .
http://www.pharmtech.com/pharmtech/Company+and+People+Notes/GSK-Acquires-Vaccine-Platform-Tech-Company-Okairos/ArticleStandard/Article/detail/814441?ref=25
http://www.pharmtech.com/pharmtech/Company+and+People+Notes/GSK-Acquires-Vaccine-Platform-Tech-Company-Okairos/ArticleStandard/Article/detail/814441?ref=25
No comments:
Post a Comment